

**Douglas A. Arenberg, M.D.**  
Associate Professor of Internal Medicine,  
Division of Pulmonary and Critical Care Medicine  
Medical Director Lung Cancer Screening Program  
University of Michigan Health System  
1150 W. Medical Center Drive, 6301 MSRB III  
Ann Arbor, MI, 48109-0642  
(734) 936-5047; fax (734) 764-2655  
[darenber@umich.edu](mailto:darenber@umich.edu)

Title and Contents	1
Education and Training	2
Certification and Licensure	2
Academic, Administrative, and Clinical Appointments	2
Research Interests	2
Grants	3
Honors and Awards	3
Memberships in Professional Societies	4
Editorial Positions, Boards, and Peer-Review Services	4
Teaching	5
Committee, Organizational, and Volunteer Services	5
Visiting Professorships, Seminars, and Extramural Invited Presentations	7
Bibliography	8

**Douglas A. Arenberg, M.D.**

Associate Professor of Internal Medicine,  
Division of Pulmonary and Critical Care Medicine  
Medical Director Lung Cancer Screening Program  
Director of Pulmonary Diagnostic Procedures Unit  
University of Michigan Health System  
1150 W. Medical Center Drive, 6301 MSRB III  
Ann Arbor, MI, 48109-0642  
(734) 936-5047; fax (734) 764-4556  
[darenber@umich.edu](mailto:darenber@umich.edu)

**Education and Training**

5/1986	University of Illinois, Champaign, IL, B.S. Bioengineering
5/1990	University of Illinois, Chicago, IL, M.D., (graduation with honors)
8/1990 – 7/1993	University of Michigan Medical Center, Ann Arbor, MI, Residency in Internal Medicine
8/1993 – 7/1996	University of Michigan Medical Center, Ann Arbor, MI, Fellowship in Pulmonary and Critical Care Medicine

**Certification and Licensure**

1993 (2003)	American Board of Internal Medicine; Internal Medicine
1996 (2006)	American Board of Internal Medicine; Pulmonary Diseases
1997 (2007)	American Board of Internal Medicine; Critical Care Medicine
1990-	Medical Licensure: Michigan, #4301056075

**Academic, Administrative, and Clinical Appointments**

*Academic*

7/1996- 6/1997	Lecturer-Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan Medical School
7/1997- 8/2003	Assistant Professor of Internal Medicine, University of Michigan Medical School
9/2003-	Associate Professor of Internal Medicine (with tenure), University of Michigan Medical School

*Clinical*

7/1996-2014	Consulting Physician, Ann Arbor Veterans Administration Hospital, Ann Arbor, MI
-------------	---

*Administrative*

1/2015- Director of Bronchoscopy and Pulmonary Outpatient Procedure unit

**Research Interests**

1. Lung cancer early detection, biomarkers, and risk assessment.
2. Tobacco Policy and cessation practices
3. Health Risk Communication, Decision aids and Risk modeling in cancer screening

## Grants

### *Present and Active*

Michigan Department of Community Health. Health Systems Change for Tobacco Dependence Treatment and Lung Cancer Screening. PI (\$130,000. 10% effort)

### *Major Previous Grants*

8/2010-7/2014 NIH/NHLBI N01 HR-46162 Lung Tissue Research Consortium Tissue Core Director (\$413,032, 10% effort)

4/2006-3/2011 Cardiovascular Medical Research & Education Fund, Lung Tissue Transplant & Processing Center, Principal Investigator (\$150,000 annual; 10% effort)

7/2009-6/2011 NIH/NCI, 2R01 CA094121-06A2, Project Title: *Promotion of Angiogenesis in Lung Cancer by MIF*. Principal Investigator (\$178,000 annual direct; 50% effort)

7/2002-6/2007 NIH/NCI, R01 CA94121, Project Title: *Promotion of Angiogenesis in Lung Cancer by MIF*. Principal Investigator (\$178,000 annual direct; 50% effort)

7/2004-6/2007 Flight Attendant's Medical Research Institute. Project Title: *A Transgenic Mouse Model to Control the Angiogenic Switch in Lung Cancer*, Principal Investigator, (\$100,000/year; 20% effort)

7/2005-6/2007 ACCP/LUNGeVity Foundation, *Profiling the Phenotype of Tumor Derived Stromal Fibroblasts* (\$75,000 annual; 0%effort)

7/1998-6/2000 The Sidney Kimmel Foundation for Cancer Research, Project Title: *The Role of Non-malignant Cells in Tumorigenesis*, Principal Investigator (\$200,000 direct; 10% effort)

4/1997-3/2002 NIH/NCI Research Career Award (RCA), K08 CA72543 Project Title: *IP-10 is an Angiostatic Factor in Lung Cancer*, Principal Investigator (\$405,000 direct; 80% effort)

4/2004-3/2005 Department of Internal Medicine Innovative Grants Program, *Animal Model of the Angiogenic Switch in Lung Cancer*, (\$40,000, 0% effort)

## Honors and Awards

1983-1986 Dean's List, University of Illinois

1986 Phi Kappa Phi Honor Society

1987 McGraw-Hill Book Award for first year class

1989 Otto Saphir Memorial Scholarship

1989 Alpha Omega Alpha Medical Honor Society

1990 Senior Honor Award Nominee

1993 Award for Outstanding Senior Resident Research Project

1993 AFMR Henry Christian Award for Excellence in Cancer Research

1998 Kimmel Foundation Scholar

1999 Central Society for Clinical research

2000 AFMR Physician-Investigator Award for Excellence in Research

2004 TAMS award (Token of Appreciation from Medical Students)

2013-2015 America's best Doctors

2015 Pulmonary & Critical Care Fellow's Outstanding Teaching Award

2015 HOUR Detroit Top Doctors 2015

2016 Department of Internal Medicine. Society of Clinical Excellence

## Memberships in Professional Societies

1982	Delta Chi Fraternity
1989	Alpha Omega Alpha Medical Honor Society
1992	American College of Physicians
1993	American Thoracic Society
1993	American College of Chest Physicians-Fellow
1998	American Association of Immunologists
1998	American Federation for Medical research
1999	Central Society for Clinical research
2003	American Association for Cancer Research
2007	International Association for the Study of Lung Cancer

## Editorial Positions, Boards, and Peer-Review Services

Editorial Boards                      *Respiratory Medicine, Associate Editor*

Reviewer (recent)

*American Journal of Pathology*  
*American Journal of Respiratory Cell & Molecular Biology*  
*American Journal of respiratory & Critical Care Medicine*  
*Chest*  
*Clinical Cancer Research*  
*European Respiratory Journal*  
*Oncology*  
*Journal of the National Cancer Institute*  
*Journal of Thoracic Oncology*  
*PLoS One Medicine*  
*New England Journal of Medicine*

Peer Grant review

1998, 2001	VA Merit review, <i>ad hoc</i>
1999-2001	California Tobacco-Related Disease Research Program
2001.	UK Cancer research Campaign <i>Ad hoc</i> reviewer.
2/2004	Pennsylvania Department of Health (PADOH), Centers of Excellence in Lung Research
2004	PADOH Centers of Excellence, Allegheny-Singer research Institute, Interim Performance Review
2005	Australian National Health and Medical Research Council <i>ad hoc</i> FAMRI grant review study section
2006	American Lung Association Research Award Study Section
2007	Pennsylvania Dept. of Health Tobacco Research Performance Review
2008-2009	NIH- NCI SPORE study section, February and June 2008
2008-2010	American Lung Association Research Award Study Section
2009	NIH-NCI Clinical Studies PO-1 special emphasis panel
2010	NCI-I Career Development Award study Section
2010	NIH/NCI Tumor Microenvironment Study Section, Ad Hoc
2011	LUNGevity Discovery award study section,
2011	NCI-I Career Development Award study Section, Ad Hoc
2011	Science Fund Ireland, Site Visit
2012	Ad Hoc ACRIN-NLST Biorepository reviewer
2012-2014	Chair, American Lung Association Lung Cancer Award study section
2012	NCI-I Career Development Award study Section, Ad Hoc

<i>Other</i>	University of Michigan Comprehensive Cancer Center: Tumor Immunology Program, & Thoracic Oncology Program. University of Michigan Clinical Angiogenesis (group organizer, symposium organizer)
4/2000	Experimental Biology 2000, San Diego, CA: <i>Therapeutic Manipulation of Angiogenesis</i>
7/2004-ongoing	University of Michigan Department of Radiation Oncology Data Safety Monitoring Board
4/2005	Michigan Proteomics Alliance for Cancer Research (PACR)
2014-present	American College of Radiology ACRIN PA-Data Safety Monitoring Board

## **Teaching**

### *University of Michigan (Recent)*

July 1996-present	Attending Physician, Bronchoscopy Service
Dec 24-Jan 6 2014	Attending physician, Pulmonary inpatient unit
February 4-17 2014	Attending physician, Critical Care Medicine Unit
August 8, 2014	Internal Medicine, Departmental Grand Rounds. Lung Cancer Screening
December 2015	Attending physician, Critical Care Medicine Unit
January 2015-	Post-doctoral candidate committee, Joanne Chen, School of Public Health
January 2015	Attending physician, Critical Care Medicine Unit
January 2016-	Radiology Faculty Mentoring Committee: Mohammad Sayyouh, M.D.
2014-present	Pulmonary Fellowship Clinical Competency Committee
Janury 2015-present	Thesis Committee Sara Cheng, Doctoral Candidate, Epidemiology, School of Public Health

### *Divisional Conferences (recent, selected)*

2015	Clinical core lecture: Lung Cancer
2015	Clinical core lecture: Lung Cancer Screening
2015	Jan 11 <sup>th</sup> & 27 <sup>th</sup> Internal Medicine Resident Noon Conference

## **Committee, Organizational, and Volunteer Services**

### *State/National*

2000	American Federation for Medical Research: Experimental Biology Program Planning Committee.
2004-present	NIH/NHLBI Lung Tissue Research Consortium, Steering Committee, and Tissue Working Group
4/2005	ACCP Evidence-Based Guidelines Committee: Diagnosis and Management of Lung Cancer: ATS representative.
10/07	ACCP Thoracic Oncology Network Steering Committee
5/2008-present	ATS Respiratory Cell and Molecular Biology (RCMB) Programming committee
5/2008-present	ATS, RCMB Lung Cancer Working Group
7/2008	ATS Lung cancer task force
10/2008	ACCP Thoracic Oncology Network, Vice Chair 2008-2010
2010-2012	ACCP Evidence Based Lung Cancer Guidelines Editor
10/2010	ACCP Thoracic Oncology Network, Chair 2010-2012
2013-present	American College of Radiology Imaging Network-PA Data Safety and Monitoring Board
May 2013	ATS, Section on Thoracic Oncology Executive, Nominating Committee

2013-present	International Association for the Study of Lung Cancer (IASLC), Tobacco Control and Smoking Cessation Committee
April 2014-	Michigan Department of Public Health Cancer Consortium (MCC): Early Detection Working Group
May 2014-2015	Chair, Programming Committee, ATS Assembly on Thoracic Oncology
September 2014-	National Comprehensive Cancer Network (NCCN) Smoking Cessation Panel
2015-	IASLC; Multiple Pulmonary Tumor Sites Workgroup
2015-	ACCP Evidenced Based Lung Cancer Guidelines Executive Committee

*Medical School*

9/2004-8/2007	University of Michigan SACUA, Communications Advisory Committee
2012-present	EPIC EMR (“MiChart”) Pulmonary Physician Lead
2012-2014	UM Northville Health Center, Strategic Design Team
2014-present	UMHS Tobacco cessation practice oversight working group

*Community Service*

1986-1989	Youth Health Outreach Program, Chicago Illinois
2000	Galen’s Tag Day (fund raiser, van driver)
2000-2005	St. Kenneth Church, Parish Health Ministry
2004-2006	Northville Youth Soccer Association, Volunteer Coach
2007-2012	Northville Baseball Softball Association Volunteer Coach
2007-present	Bonnie Addario Lung cancer Foundation Honorary Board member
2011-2013	Northville Green Ribbon Commission on 7 Mile Rd Master Development Plan

**Visiting Professorships, Seminars, and Extramural Invited Presentations (*Last 5 years only*)**

3/09	Michigan Society of GI Nurses and Associates
3/09	Medical College of Milwaukee, Internal Medicine Grand Rounds
5/09	ATS International Conference, Lung cancer: Year in Review
5/09	ATS International Conference, Symposium Chair and Speaker on Tumor Microenvironment
7/09	Invited lecture: IASLC World Congress on Lung Cancer. Electromagnetic Navigation.
11/09	Invited speaker: ACCP CHEST 2009 Post-graduate symposium on lung cancer
2/2010	Invited Speaker, Electromagnetic Navigation users meeting, Orlando, FL
5/2010	Invited Speaker, Bay Pines VA, Medicine Grand Rounds
9/2010	Invited Speaker, Tulane University Pulmonary Grand Rounds
10/2010	Columbus regional Hospital, Annual Thoracic Conference, Invited speaker
10/2010	Columbus Regional Hospital, Indianapolis, Indiana. Grand rounds
11/2010	ACCP CHEST 2010 Invited Speaker, “Ethnic Differences in Lung Cancer”
2/2011	Navigational bronchoscopy summit; Probe-based confocal laser endoscopy
5/2011	American Thoracic Society International Conference. Meet the Professor seminar
July 2011	IASLC World Congress on Lung Cancer, Biomarker and Screening workshops. Amsterdam, Netherlands.
10/2011	ACCP CHEST 2012 Chair and Invited Speaker. Personalized treatment for Lung cancer, Honolulu, HI
10/2011	ACCP CHEST 2012 Chair and Invited Speaker. Update on the National Lung Screening Trial
10/2011	ACCP CHEST 2012 Chair and Invited Speaker. Post-graduate course: Update in Lung cancer ‘

2/2012 Symposium Co-chair and Invited Speaker. Electromagnetic Navigation Summit, Jacksonville, FL (Speaker on Best Practices for Lung Cancer Screening)

2/2012 Invited Speaker: Pulmonologists role in lung cancer. IMPACT 2012, Singapore, Singapore.

5/2012 Invited Speaker: Lung Cancer Screening American Thoracic Society

9/2012 Invited Speaker, Beaumont Chest Conference, Lung Cancer Screening

10/2012 Invited Speaker: Lung Cancer Risk Assessment American College of Chest Physicians

10/2012 Invited Speaker. American Physicians Institute Pulmonary Board Review

9/2012-3/2013 Invited Chair and Conference organizer. Electromagnetic Navigation Summit. Tucson, AZ: Controversies in the Treatment of Lung Cancer

5/2013 Invited Speaker American Thoracic Society International Conference. Post-Graduate Course. Lung Cancer State of the Art

5/2013 Invited Speaker, Wayne State University, Karmanos Cancer Center. "New Directions in Lung Cancer Research" Lung Cancer Screening

5/2013 ATS Post-Graduate Course. Lung cancer Screening: Evidence Based Review

5/2013 ATS International Conference. Clinical Challenges, Practicing in the Absence of data: *Stage III lung cancer; Who gets surgery?*

5/2013 ATS International Conference, Symposium Chair and speaker: Lung cancer Screening: Moving Forward.

7/2013 *Internal Medicine Update*, Mackinac Island, MI

8/2013 Invited Speaker. American Physicians Institute Pulmonary Board Review, Chicago, IL

9/2013 Invited Speaker: Synergistic Perspectives in NSCLC Management, Chicago, IL

10/2013 Invited Speaker: St. Vincent's Hospital, 4th Annual International Respiratory Meeting. Dublin, Ireland

10/2013 ACCP CHEST 2013 Invited Speaker. Diagnostic Approach to the Patient With Suspected Lung Cancer

10/2013 ACCP CHEST 2013 Invited Speaker. Lung Cancer Screening: Practical Lessons From Early Experiences

10/2013 ACCP CHEST 2013 Chair and Invited Speaker. Present and Future Targeted Lung Cancer Therapy: Beginning the End of Nihilism

10/2013 ACCP CHEST 2013 Chair and Invited Speaker. PET Scans: The Swiss Army Knife of Thoracic Oncology

10/2013 ACCP CHEST 2013 Speaker. ACCP Lung Cancer III Guidelines: Treatment of Early Lung Cancer (NSCLC)

11/2013 St. Mary's Saginaw Hospital 19th Annual Fall Oncology Symposium. Chair and Speaker

3/2014 Chair and Speaker, Institute for Medical Education, Electromagnetic Navigation Summit. San Antonio Texas: Diagnosis and Management of Lung Cancer

5/2014 Invited Speaker and participant, ATS Workshop on Implementation of Lung Cancer Screening

9/2014 Atlantic Medical Imaging: Invited Speaker: Lung Cancer Screening

10/2014 ACCP CHEST 2014 Chair and Invited Speaker. PET Scans: The Swiss Army Knife of Thoracic Oncology

2/2015 Michigan Academy of Family Practice Winter Update: Invited Speaker

3/2015 American Society of Preventive Oncology: Invited Speaker "Lung Cancer Screening"

3/2015 University of Alabama-Birmingham, Pulmonary Conference speaker

June 2015 ENB Summit Speaker on Lung Cancer Screening and Pro-Con debate

June 2015 Sheba University, Tel Hashomer, Israel. Confocal Endomicroscopy Meeting

September 2015	UM Family Practice Departmental Grand Rounds. Lung Cancer Screening
October 2015-present	Faculty, Inaugural University of Michigan Tobacco Treatment Specialist Course
December 2015	Radiological Society of North America, Annual Meeting. Chicago. Invited Speaker
December 2015	Michigan Academy of Family Practice: Primary Care for Women. Invited Speaker: Lung Cancer Screening and Risk Reduction
May 2016	XI Buenos Aires Conference, Multidisciplinary Approach to Lung Cancer
June 2016	Invited Professor, Sichuan Academy of Medical Sciences, Pulmonary Medicine Course, Chengdu China
July 2016	Faculty, UM Department of Internal Medicine, Board Review Course

## Bibliography

### *Completed Publications in Scientific Journals: Peer-Reviewed*

1. Al-Bazzaz FJ, Veech J, Arenberg DA. Collapse of intercellular spaces of canine tracheal mucosa by epinephrine. *J Appl Phys* 1988; 65(3):1274-80.
2. Standiford TJ, Arenberg DA, Danforth J, Kunkel SL, VanOtteren G, Strieter RM. Lipoteichoic acid induces the secretion of interleukin-8 from human blood monocytes: A cellular and molecular analysis. *Infect Immunol* 1994; 62(1):119-25.
3. Smith DR, Kunkel SL, Standiford TJ, Rolfe MW, Lynch JP III, Arenberg DA, Wilke CA, Burdick MD, Martinez FJ, Hampton JN, Whyte RI, Orringer MB, Strieter RM. Increased interleukin-1 receptor antagonist in idiopathic pulmonary fibrosis: A compartmental analysis. *Am J Respir Crit Care Med* 1995; 151(6):1965-73.
4. Danforth J, Strieter RM, Kunkel RM, Arenberg DA, VanOtteren G, Standiford TJ. Macrophage inflammatory protein-1 alpha expression in vivo, and in vitro: The role of lipoteichoic acid. *Clin Immunol Immunopathol* 1995; 74(1):77-83.
5. Arenberg DA, Kunkel SL, Standiford TJ, Burdick MD, Strieter RM. Regulation of monocyte derived IL-1 receptor antagonist by cisplatin. *Cytokine* 1995; 7(1):89-96.
6. Strieter RM, Kunkel RM, Arenberg DA, Burdick MD, Polverini PJ. Interferon- $\gamma$  inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. *Biochem Biophys Res Com* 1995; 210(1):51-57.
7. Strieter RM, Polverini PJ, Shanafelt A, Arenberg DA, Walz A, Opdenakker G, Van Damme J, Kunkel SL. The role of C-X-C chemokines as regulators of angiogenesis in lung cancer. *J Leuk Biol* 1995; 57(5):752-62.
8. Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, Dzuiba J, Van Damme J, Walz A, Marriott D, Chan S, Rocznik S, Shanafelt A. The functional role of the 'ELR' motif in CXC chemokine mediated angiogenesis. *J Bio Chem* 1995; 270(45):27348-57.
9. Strieter RM, Polverini PJ, Arenberg DA, Kunkel SL. The role of CXC chemokines as regulators of angiogenesis. *Shock* 1995; 4(3):155-60.
10. Arenberg DA, Kunkel SL, Polverini PJ, Glass M, Burdick MD, Strieter RM. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. *J Clin Invest* 1996; 97:2792-2802.
11. Arenberg DA, Kunkel SL, Polverini PJ, Morris SB, Burdick MD, Glass M, Taub DT, Iannettoni MD, Whyte RI, Strieter RM. Interferon- $\gamma$  inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. *J Exp Med* 1996; 184(3):981-92.
12. Keane MP, Arenberg DA, Lynch JP III, Whyte RI, Iannettoni MD, Burdick MD, Wilke CA, Morris SB, Glass MC, DiGiovine B, Kunkel SL, Strieter RM. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. *J Immunol* 1997; 159:1437-43.
13. Arenberg DA, Polverini PJ, Kunkel SL, Shanafelt A, Hesselgesser J, Horuk R, Strieter RM. The role of CXC Chemokines in the regulation of angiogenesis in non-small cell lung cancer. *J Leuk Biol* 1997; 62(5):554-62.



14. Arenberg DA, Polverini PJ, Kunkel SL, Shanafelt A, Strieter RM. In vitro and in vivo systems to assess the role of CXC chemokines in the regulation of angiogenesis. *Meth Enzymol* 1997; 288:190-220.
15. Moore BB, Arenberg DA, Strieter RM. The role of CXC chemokines in the regulation of angiogenesis in association with non-small cell lung cancer. *Trends Cardiovasc Med* 1997; 62(5):554-62.
16. Peer Reviewed (continue Moore BB, Keane MP, Addison CA, Arenberg DA, Strieter RM. CXC chemokine modulation of angiogenesis: The importance of a balance between angiogenic and angiostatic members of this family. *J Inv Med* 1998; 46(4):113-120.
17. Arenberg DA, Keane MP, DiGiovine B, Kunkel SL, Morris SM, Xue Y, Burdick MD, Glass MC, Iannettoni MD, Strieter RM. Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. *J Clin Invest* 1998; 102(3):465-472.
18. Keane MP, Arenberg DA, Moore BB, Addison CL, Strieter RM. CXC Chemokines and angiogenesis/angiostasis. *Proc Assoc Am Phys* 1998; 110:288-296.
19. Moore BB, Arenberg DA, Addison CA, Keane MP, Strieter RM. Tumor angiogenesis is regulated by CXC chemokines. *J Lab Clin Med* 1998; 132:97-103.
20. Moore BB, Arenberg DA, Addison CL, Keane MP, Polverini PJ, Strieter RM. CXC chemokines mechanism of action in regulating tumor angiogenesis. *Angiogenesis* 1998; 2:123-134.
21. Keane MP, Belperio JA, Moore TA, Moore BB, Arenberg DA, Smith RE, Burdick MD, Kunkel SL, Strieter RM. Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis. *J Immunol* 1999; 162:5511-5518.
22. Moore BB, Arenberg DA, Stoy K, Morgan, T, Addison CL, Morris SB, Glass M, Wilke C, Xue YY, Sitterding S, Kunkel SL, Burdick MD, Strieter RM. Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. *Am J Pathol* 1999; 154(5):1503-1512.
23. Strieter RM, Addison CA, Ehlert JE, Keane MP, Belperio JA, Burdick MD, Arenberg DA. The use of immunodeficient mice for the evaluation of CXC chemokines in the regulation of tumor-associated angiogenesis. *Inst fLab Animal Res J* 1999; 40(4):175-182.
24. Keane MP, Belperio JA, Arenberg DA, Burdick MD, Xu ZJ, Xue YY, Strieter RM. IFN- $\gamma$ -inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. *J Immunol* 1999; 163:5686-5692.
25. Addison C, Arenberg DA, Morris SB, Xue Y, Burdick MD, Mulligan MS, Iannettoni MD, Strieter RM. The CXC chemokine, monokine induced by interferon gamma (MIG), inhibits non-small cell lung cancer (NSCLC) tumor growth and metastasis. *Hum Gene Ther* 2000; 11(2):247-61.
26. Arenberg DA, Keane MP, DiGiovine B, Kunkel SL, Strom SR, Burdick MD, Iannettoni MD, Strieter RM. Macrophage infiltration in human non-small cell lung cancer: The role of CC chemokines. *Cancer Immunol Immunother* 2000; 49(2):63-70.
27. Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD, Strieter RM. CXC chemokines in angiogenesis. *J Leuk Biol* 2000; 68:1-8.
28. Arenberg DA, Zlotnick A, Strom SR, Burdick MD, Strieter RM. The murine CC chemokine, 6C-kine, inhibits tumor growth and angiogenesis in a human lung cancer model. *Cancer Immunol Immunother* 2001; 49(11):587-592.
29. White EW, Strom SR, Wys NB, Arenberg DA. Non-small cell lung cancer cells induce monocytes to increase expression of angiogenic activity. *J Immunol* 2001; 166(12):7549-7555.
30. Schteingart DE, Giordano TJ, Benitez R, Burdick M, Starkman MN, Arenberg DA, Strieter RM. Overexpression of CXC-chemokines by an adrenocortical carcinoma: A novel clinical syndrome. *J Clin Endocrinol Metab* 2001; 86:3968-3974.
31. White EW, Livant DL, Markwart S, Arenberg DA. Monocyte-fibronectin interactions, via  $\alpha_5\beta_1$  integrin, induce expression of CXC chemokine dependent angiogenic activity. *J Immunol.* 2001; 167(9):5362-5366.
32. Arenberg DA, White ES, Burdick MD, Strom SR, Strieter RM. Improved survival in tumor bearing SCID mice treated with interferon- $\gamma$ -inducible protein 10 (IP-10/CXCL10). *Cancer Immunol Immunother* 2001; 50(10):533-538.
33. White EW, Strieter RM, Arenberg DA. Chemokines as therapeutic targets in non-small cell lung cancer. *Curr Med Chem Anticancer Agents* 2002; 2(3):403-417.
34. Moran CJ, Arenberg DA, Huang C, Giordano TJ, Thomas DG, Misek DE, Hanash S, Iannettoni MD, Orringer MB, Beer DG. RANTES expression by lung adenocarcinoma is a predictor of survival in stage I

- patients. *Clin Can Res* 2002 (8):3803-3812.
35. White ES, Flaherty KR, Carskadon S, Brant A, Iannettoni MD, Yee J, Orringer MB, Arenberg, DA. Macrophage migration inhibitory factor (MIF) and CXC chemokine expression in human non-small cell lung cancer (NSCLC): role in angiogenesis and prognosis. *Clin Can Res* 2003; 9(2): 853-860.
  36. White ES, Carskadon SL, Dickey EG, Livant DL, Markwart S, Arenberg DA. Integrin  $\alpha_4\beta_1$  regulates basement membrane invasion by fibrotic-lung fibroblasts: A role for PTEN. *Am J Resp Crit Care Med* 2003; 168:436-442.
  37. Keshamouni VG, Reddy RC, Arenberg DA, Joel B, Thannickal VJ, Kalemkerian GP, Standiford TJ. Peroxisome proliferator activated receptor-gamma activation inhibits tumor progression in non-small cell lung cancer. *Oncogene* 2004; 23(1):100-8.
  38. Cronin P, Arenberg D. Pulmonary epithelioid hemangioendothelioma: an unusual case and a review of the literature. *Chest* 2004; 125(2): 789-792.
  39. Henke PK, Varga A, De S, Arenberg DA, Sukheepod P, Kunkel S, Upchurch GR, Wakefield TW. Deep vein thrombosis resolution is modulated by monocyte CXCR2-mediated activity in a mouse model. *Arterioscler Thromb Vasc Biol* 2004; 24(6):1130-1137.
  40. Arenberg DA. Chemokines as therapeutic targets in non-small cell lung cancer. *Med Chem Rev Online* 2004; 1:253-256.
  41. Arenberg DA. Evaluating the patient with suspected lung cancer. *J Resp Dis* 2004; 25(7):266-272.
  42. Arenberg DA. Lung cancer: selecting patients for surgery. *J Resp Dis* 2004; 25(8): 337-345.
  43. Marcus B, Arenberg DA, Kleer C, Chepeha DB, Schmalbach CE, Pan Q, Hanash S, Kuick R, Lee J, Merajver SD, Teknos TN. Prognostic factors in oral cavity and oropharyngeal squamous cell carcinoma: the impact of tumor-associated macrophages. *Cancer* 2004; 101(12):2779-87.
  44. Teknos TN, Islam M, Arenberg DA, Pan Q, Carskadon SL, Abarbnell AM, Marcus B, Paul S, Vadenburg CD, Nor JE, Merajver SD. Tetrathiomolybdate (TM) modulates cytokine expression, angiogenesis and tumor growth in squamous cell carcinoma of the head and neck. *Arch Otolaryngol Head Neck Surg* 2005; 131(3):204-11.
  45. Keshamouni VG, Arenberg DA, Reddy RC, Newstead MJ, Anthwal S, Standiford TJ. PPAR- $\gamma$  activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer. *Neoplasia*. 2005; 7(3):294-301.
  46. Kong FM, Hayman, JA Griffith KA, G. P. Kalemkerian, D. Arenberg, S. Lyons, A. Turrisi, A. Lichter, B. Fraass, A. Eisbruch, T. S. Lawrence, and R. K. Ten Haken. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): Predictors for radiation pneumonitis and fibrosis. 2006.*Int J Radiat Oncol Biol Phys In Press* Apr 26, 2006; [Epub ahead of print].
  47. Keshamouni VG, G. Michailidis CS, Grasso S, Anthwal JR, Strahler A, Walker, Arenberg DA, Reddy RC, Akulapalli S, Thannickal VJ, Standiford TJ, Andrews PC, Omenn GS. Differential Protein Expression Profiling by iTRAQ-2DLC-MS/MS of Lung Cancer Cells Undergoing Epithelial-Mesenchymal Transition Reveals a Migratory/Invasive Phenotype. *J Proteome Res* 2006;5(5):1143-1154.
  48. Arenberg DA. Chemokines in the biology of lung cancer. *J Thoracic Onc*. 2006;1(4):87-88.
  49. McClelland MR, Carskadon SL, Zhao I, White ES, Beer EG, Orringer MB, Pickens A, Chang AC, Arenberg DA. Diversity of the Angiogenic Phenotype in Non-Small Cell Lung Cancer. *Am J Respir Cell Mol Biol* 2007;36:343-350, PMID: 17179777
  50. Arenberg DA. Bronchioloalveolar Lung Cancer: ACCP Evidence-based Clinical Practice Guidelines. Diagnosis and Management of Lung Cancer: Evidence Based Guidelines. *Chest*. 2007; 132:306S-313. PMID: 17873176
  51. Zhaoa L, Sheldon K, Chen M, Yina MS, Hayman JA, Kalemkerian GP, Arenberg DA, Lyons S, Curtis JL, Davis M, Cease K, Brenner D, Anschere MS, Lawrence TS, Kong FM. The Predictive Role of Plasma TGF- $\beta_1$  During Radiation Therapy for Radiation-induced Lung Toxicity Deserves Further Study in Patients with Non-small Cell Lung Cancer. *Lung Cancer*. 2008; 59(2) 232-239. PMID 17905467
  52. McClelland MR, Zhao L, Carskadon SL, Arenberg DA. Expression of CD74, the Receptor for Macrophage Migration Inhibitory Factor (MIF), in Non-Small Cell Lung Cancer. *Am J Pathol*. 2009;174(2):638-46. PMID: 19131591,PMCID: 2630571

53. Freeman CM, Martinez FJ, Han MK, Ames TM, Chensue SW, Todt JC, Arenberg DA, Meldrum CA, Getty C, McCloskey L, Curtis JL. Lung Dendritic Cell Expression of Maturation Molecules Increases with Worsening COPD. *Am J Respir Crit Care Med.* 2009; 180:1179-1188. PMID: 27976731
54. Wang L, Correa CR, Hayman JA, Zhao L, Cease K, Brenner D, Arenberg D, Curtis J, Kalemkerian GP, Kong FM. Time to Treatment in Patients with Stage III Non-small Cell Lung Cancer. *Int J Radiat Oncol Biol Phys.* 2009 Jul 1;74(3):790-5. PMID: 3381995
55. Kulasekaran P, Scavone CA, Rogers DS, Arenberg DA, Thannickal VJ, Horowitz JC. Endothelin-1 and Transforming Growth Factor-beta1 Independently Induce Fibroblast Resistance to Apoptosis via AKT Activation. *Am J Respir Cell Mol Biol.* 2009; 41(4):484-93. PMID: 2744991
56. Arenberg, DA. Electromagnetic Navigation Guided Bronchoscopy. *Cancer Imaging.* 2009; 6;9:89-95. PMID: 19933023
57. Bauman K, Arenberg D. Multidisciplinary Evaluation of Patients with Suspected Lung Cancer. *Clin Pulm Med.* 2010 1;17(1):35-41. PMID: 28208634
58. Freeman CM, Han MK, Martinez FJ, Murray S, Liu LX, Chensue SW, Polak TJ, Sonstein J, Todt JC, Ames TM, Arenberg DA, Meldrum CA, Getty C, McCloskey L, Curtis JL. Cytotoxic Potential of Lung CD8+ T Cells Increases with Chronic Obstructive Pulmonary Disease Severity and with In Vitro Stimulation by IL-18 or IL-15. *J Immunol.* 2010; 184(11):6504-13, PMID 20427767, PMID: PMC4098931
59. Arenberg DA, McMillan T, Carskadon SL, Zhao L, Amin M, Koch AE. Macrophage Migration Inhibitory Factor Promotes Tumor Growth in the Context of Lung Injury and Repair. *American Journal of Respiratory and Critical Care Medicine.* *Am J Respir Crit Care Med.* 2010 15;182(8):1030-7. PMID: 2970845
60. Montgrain PR, Deftos LJ, Arenberg DA, Tipps A, Quintana R, Carskadon S, Hasting RH. Prognostic Implications of Parathyroid Hormone-related Protein in Males and Females With Non-small-cell Lung Cancer. *Clin Lung Cancer* 2011; 12(3):197-205 PMID 21663864
61. Betz BL, Roh MH, Weigelin HC, Placido JB, Schmidt LA, Farnen S, Arenberg DA, Kalemkerian GP, Knoepp SM. The Application of Molecular Diagnostic Studies Interrogating EGFR and KRAS Mutations to Stained Cytologic Smears of Lung Carcinoma. *Am. J. Clin Pathol.* 2011; 136(4):564-71 PMID: 21917678
62. Yuan ST, Frey KA, Gross MD, Hayman JA, Arenberg DA, Curtis JL, Cai XW, Ramnath N, Kalemkerian GP, Ten Haken RK, Eisbruch A, Kong FM. Semiquantification and Classification of Local Pulmonary Function by V/Q Single Photon Emission Computed Tomography in Patients with Non-small Cell Lung Cancer: Potential Indication for Radiotherapy Planning. *J Thorac Onco.* 2011; 6(1)71-8 PMID: 3351273
63. Arenberg DA. Bronchioloalveolar Carcinoma. *Semin Respir Crit Care Med.* 2011; 32(1):52-61, PMID 21500124
64. Arenberg DA. PET Scans for Lung Nodules: Cost and Cost Effectiveness. *Chest* 2012; 137(1): 4-6. PMID 20051397
65. Arenberg DA, Kazerooni E. Setting up a Lung Cancer Screening Program. *J Natl Compr Canc Netw.* 2012;10:277-285 PMID: 22308520
66. Chang AC, Sundaram B, Arenberg DA. Lung Cancer: Multidisciplinary Approach to Tissue Sampling. *Radiol Clin North Am.* 2012; 50(5): 951-60. PMID: 22974780
67. Wang J, Cao J, Yuan S, Ji W, Arenberg DA, Dia J, Stanton P, Tatro D, Ten Haken RK, Wang L, Fong FM. Poor Baseline Pulmonary Function May Not Increase the Risk of Radiation-Induced Lung Toxicity. *Int J Radiat Onco Biol Phys.* 2012; [Epub ahead of print] PMID: 22836048, PMID: PMC3646086
68. Roh MH, Schmidt L, Placido J, Farnen S, Fields KL, Courey A, Arenberg DA, Knoepp SM. The Application and Diagnostic Utility of Immunocytochemistry on Direct Smears in the Diagnosis of Pulmonary Adenocarcinoma and Squamous Cell Carcinoma. *Diagn Cytopathol.* 2012; 40(11):949-55 PMID: 21500373
69. Yuan ST, Frey KA, Gross MD, Hayman JA, Arenberg DA, Cai XW, Ramnath N, Hassan K, Moran J, Eisbruch A, Ten Haken RK, Kong FM. Changes in Global Function and Regional Ventilation and Perfusion on SPECT During the Course of Radiotherapy in Patients with Non-small Lung Cancer. *Int J*

*Radiat Onco Biol Phys.* 2012; 82(4):e631-8. PMID: 3381888

70. Ramnath N, Dilling T, Harris L, Kim A, Michaud G, Balekian A, Detterbeck F, Diekemper R, Arenberg DA. American College of Chest Physicians: Diagnosis and Management of Lung Cancer: Treatment of Stage III Non-Small Cell Lung Cancer. ACCP Evidence-based Clinical Practice Guidelines (3<sup>rd</sup> Edition). *Chest.* 2013 May;143(5 Suppl):e314S-40S. doi: 10.1378/chest.12-2360. PMID: 23649445
71. Horowitz J, Kleaveland K, Arenberg DA. Safe Endobronchial Ultrasound (EBUS) Guided Biopsy of An Intra-Pulmonary Arterial Mass. *J Bronchology Interv Pulmonol.* 2013. 20(1); 93–95 doi: 10.1097/LBR.0b013e3182814b02 PMID: 23328154
72. Freeman CM, Martinez FJ, Han MK, Washko, George R, McCubbrey, AL, Chensue, SW, Arenberg, DA, Meldrum, CA, Dijkstra, AE, Postma, DS. Lung CD8+ T cells in COPD have increased expression of bacterial TLRs. *Respiratory Research* 2013; 14(1):1-13 PMID: 23374856, PMID: PMC3583694
73. Arenberg DA. Lung Cancer Screening. *Semin Respir Crit Care Med* 2013;34:727–737. PMID: 24258563
74. Arenberg DA. Implementation of a Lung Cancer-Screening Program. *Current Surgery Reports* 2013; 1(4):233-241
75. Quint LE, Reddy RM, Lin J, Arenberg DA, Speers C, Hayman JA, Kong FP, Orringer MB, Kalemkerian GP. Imaging in thoracic oncology: case studies from Multidisciplinary Thoracic Tumor Board (part 1 of 2 part series). *Cancer Imaging* 2013; 13(3):429-439 PMID: 24325900, PMID: 3858104
76. Quint LE, Reddy RM, Lin J, Arenberg DA, Speers C, Hayman JA, Kong FP, Orringer MB, Kalemkerian GP. Imaging in thoracic oncology: case studies from Multidisciplinary Thoracic Tumor Board: (part 2 of 2 part series). *Cancer Imaging* 2013; 13(3):440-447 PMID: 24325879, PMID: PMC3858864
77. Kinsey CM, Arenberg DA. EBUS-TBNA for Non-Small Cell Lung Cancer Staging. *Am J Respir Crit Care Med.* 2014 Mar 15;189(6):640-9. (Cover Featured Article) PMID: 24484269.
78. Mazzone PJ, Vachani A, Chang A, Detterbeck F, Cooke D, Howington J, Dodi A, Arenberg, DA. Quality Indicators for the Evaluation of Patients With Lung Cancer. *Chest.* 2014;146(3):659-669. doi:10.1378/chest.13-2900 PMID: 24700172 [in process]
79. Lau YK, Caverly TJ, Cherng ST, Cao P, West M, Arenberg D, Meza R. Development and Validation of a Personalized, Web-Based Decision Aid for Lung Cancer Screening Using Mixed Methods: A Study Protocol *JMIR Res Protoc*, 2014 Dec; 3(4):e78 PMID: 25532218 [in process]
80. Freeman CM, McCubbrey AL, Crudington S, Nelson J, Martinez FJ, Han MK, Washko GR Jr, Chensue SW, Arenberg DA, Meldrum CA, McCloskey L, Curtis JL. Basal gene expression by lung CD4+T cells in chronic obstructive pulmonary disease identifies independent molecular correlates of airflow obstruction and emphysema extent. *PLoS One* 2014 May;9(5):e96421 PMID: 24805101, PMID: PMC4013040
81. Freeman CM, Stolberg VR, Crudington S, Martinez FJ, Han MK, Chensue SW, Arenberg DA, Meldrum CA, McCloskey L, Curtis JL. Human CD56+ cytotoxic lung lymphocytes kill autologous lung cells in chronic obstructive pulmonary disease. *PLoS One* 2014 Jul; 9(7):e103840 PMID: 25078269, PMID: PMC4117545
82. Kris MG, Arenberg DA, Herbst RS, Riely GJ. Emerging science and therapies in non-small-cell lung cancer: targeting the MET pathway. *Clin Lung Cancer* 2014 Nov; 15(6):475 PMID 25306384[in process]
83. Wiener RS, Gould MK, Arenberg DA, Au DH, Fennig K, Lamb CR, Mazzone P, Midthun DE, Napoli M, Ost DE, Powell CA, Rivera P, Slatore CG, Tanner NT, Vachani A, Wisnivesky JP, Yoon SH: Writing Committee: Official American Thoracic Society / American College of Chest Physicians. Official American Thoracic Society / American College of Chest Physicians Policy Statement: Implementation of Lung Cancer Screening Programs with Low-Dose Computed Tomography in Clinical Practice. 2015 *Am J Resp Crit Care Med* 2015 192(7), pp. 881-891.
84. Schneider, D. Arenberg DA. Teachable Moment. Competing Mortality in Lung Cancer Screening. Accepted, *JAMA Internal Medicine.* 2015;175(6):896-897. doi:10.1001/jamainternmed.2015.1232.
85. E. L. Crawford, A. Levin, F. Safi, M. Lu, A. Baugh, X. Zhang, J. Yeo, S. A. Khuder, A. M. Boulos, P. Nana-Sinkam, P. P. Massion, D. A. Arenberg, D. Midthun, P. J. Mazzone, S. D. Nathan, R. Wainz, G. Silvestri, J. Tita and J. C. Willey. Lung cancer risk test trial: study design, participant baseline characteristics, bronchoscopy safety, and establishment of a biospecimen repository *BMC Pulmonary*

Medicine. 2016. 16:16 DOI: 10.1186/s12890-016-0178-4

86. Lau, YK, Caverly TJ, Cherng ST, Cao P, West M, Arenberg DA, Meza R. Improving lung cancer screening decision-making through a personalized, web-based decision aid. Submitted. *Am J Preventive Medicine*. December 2015, 49(6), Pages e125–e129
87. Detterbeck FC, Bolejack V, Arenberg DA, Crowley J, Donington JS, Franklin WA, Girard N, Marom EM, Mazzone PJ, Nicholson AG, Rusch VW, Tanoue LT, Travis WD, Asamura H, et al. The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. *Journal of Thoracic Oncology*.11(5):681-92. doi: 10.1016/j.jtho.2015.12.114.
88. Detterbeck FC, Franklin WA, Nicholson AG, Girard N, Arenberg DA, Travis WD, Mazzone PJ, et al. The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. *Journal of Thoracic Oncology*.11(5):651-65. doi: 10.1016/j.jtho.2016.01.025.
89. Detterbeck FC, Marom EM, Arenberg DA, Franklin WA, Nicholson AG, Travis WD, et al. The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Application of TNM Staging Rules to Lung Cancer Presenting as Multiple Nodules with Ground Glass or Lepidic Features or a Pneumonic Type of Involvement in the Forthcoming Eighth Edition of the TNM Classification. *Journal of Thoracic Oncology*.11(5):666-80. doi: 10.1016/j.jtho.2015.12.113.
90. Detterbeck FC, Nicholson AG, Franklin WA, Marom EM, Travis WD, Girard N, Arenberg DA, Bolejack V, Donington JS, Mazzone PJ, Tanoue LT, et al, The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification. *Journal of Thoracic Oncology*.11(5):639-50. doi: 10.1016/j.jtho.2016.01.024.

*Completed Publications in Scientific Journals: Non –Reviewed*

None

Articles Accepted for Publication: Peer Reviewed

None

*Articles Submitted for Publication: Peer Reviewed*

None

*Chapters in Books*

1. Strieter RM, Kunkel SL, Shanafelt AB, Arenberg DA, Koch AE, Polverini PJ. The role of CXC chemokines in regulation of angiogenesis. In *The Role of Chemokines in Disease*. Eds. A. Koch and R. Strieter. R.G. Landes Co. Publishers, Austin, TX. 1996; pp 195-210.
2. Strieter RM, DiGiovine B, Polverini PJ, Kunkel SL, Shanafelt A, Hesselgesser J, Horuk R, Arenberg DA. CXC chemokines and lung cancer angiogenesis. In *Chemokines and Cancer*. Ed. Barrett J. Rollins. Humana Press, Totowa NJ. 1999; pp 3-19.
3. Arenberg DA, Strieter RM. Angiogenesis. In *Molecular and Cellular Basis of Inflammation*. Ed. C. Serhan and P. Ward. Humana Press, Totowa NJ. 1999; pp 29-49.
4. Arenberg DA, Strieter RM. Angiogenesis. In *Inflammation: Basic Principles and Clinical Correlates*. Third edition. Eds. J. Gallin and R. Snyderman. Lippincott Williams & Wilkins, Philadelphia, PA. 1999; pp 851-864.
5. Strieter RM, Addison CA, Moore BB, Arenberg DA. The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer. In *Chemokines in Disease: Biology and Clinical Research*. Ed. C. Hebert. Humana Press, Totowa NJ. 1999; pp 171-182.
6. Arenberg DA and Bucala R. Macrophage migration inhibitory factor (MIF). Chapter 45, In *The Cytokine Handbook, 4<sup>th</sup> edition*. Eds. A. Thomson and M. Lotze. Academic Press. London, UK. 2003; pp 1037-1048.
7. Arenberg, DA, Pickens, A. Metastatic Lung Tumors Chapter 49 in *Murray & Nadel's Textbook of*

- Respiratory Medicine*, 5<sup>th</sup> ed. Eds. Mason, R., Broaddus, V.C., King, T., Schraufnagel, D., Martin, T.R., Murray, J.F., Nadel, J.
8. Arenberg, DA. Angiogenic diversity and lung cancer metastasis in Lung Cancer Metastasis: Novel Biological Mechanisms and Impact on Clinical Practice. Eds V. Keshamouni, D. Arenberg, and G. Kalemkerian. Springer, New York, NY. 2009. ISBN: [978-1-4419-0771-4](#)
  9. Arenberg, DA. Lung cancer Treatment, Chapter 67 in *Clinical Respiratory Medicine*, 4<sup>th</sup> ed. Eds. S. Spiro, G.A. Silvestri, and A. Agusti. 2012 ISBN: [978-1-4557-0792-48](#)
  10. Arenberg, DA, Pickens, A. Metastatic Lung Tumors in *Murray & Nadel's Textbook of Respiratory Medicine*, 6<sup>th</sup> ed. Eds. Mason, R., Broaddus, V.C., King, T., Schraufnagel, D., Martin, T.R., Murray, J.F., Nadel, J. In Process 2015
  11. Arenberg, DA, Myers, J. Benign Lung Tumors Chapter 56 in *Murray & Nadel's Textbook of Respiratory Medicine*, 6<sup>th</sup> ed. Eds. Mason, R., Broaddus, V.C., King, T., Schraufnagel, D., Martin, T.R., Murray, J.F., Nadel, J. In Process 2015

*Books edited:*

1. Lung Cancer Metastasis: Novel Biological Mechanisms and Impact on Clinical Practice. V. Keshamouni, D. Arenberg, G. Kalemkerian. (Eds.) Springer, New York, NY. 2009. ISBN: [978-1-4419-0771-4](#)

*Editorials, Consensus Statements, Workshop Proceedings and Review Articles*

1. Field JK , et al IASLC CT Screening Workshop 2011: Expert Pulmonary Group. International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 report. J Thorac Oncol. 2012;7(1):10-9. PMID 22173661
2. Arenberg, DA. Invited Editorial. In search of the Holy Grail: Lung Cancer Biomarkers. *Chest* 2004; 126(2); 325-6.
3. Arenberg, DA. Invited Editorial. PET scans for solitary pulmonary nodules: Costs and cost effectiveness. 2010 137(1):4-6; doi:10.1378/chest.09-1453
4. Arenberg DA. Invited Editorial. Nodule volume measurement: pushing the pendulum. *Chest* 2014 Mar; 145(3):440-2 PMID: 24590013
5. Arenberg, DA. Invited Editorial "Searching for Red Shirts. Emphysema as a Lung Cancer Screening Criterion?" American Journal of Respiratory and Critical Care Medicine, Vol. 191, No. 8 (2015), pp. 868-869.
6. Slatore CG, Horeweg N, Jett JR, Midthun DE, Powell CA, Soylemez RS, Wisnivesky JP, Gould MK. On behalf of the ATS Ad Hoc Committee for Setting a Research Framework for Pulmonary Nodule Evaluation. An Official American Thoracic Society Research Statement: A Research Framework for Pulmonary Nodule Evaluation and Management. Am J Respir Crit Care Med. 2015 Aug 15;192(4):500-14. PMID: 26278796

*Abstracts, Preliminary Communications, Panel Discussions*

1. Arenberg DA, Navarro E, Roilides E, Thomas V, Peter J, Lee J, Francis PF, Pizzo PA, Walsh TF. Effects of G-CSF in experimental hepatosplenic candidiasis in granulocytopenic rabbits. American Society for Microbiology, Anaheim, CA, 1990.
2. Arenberg DA, Kunkel SL, Standiford TJ, Burdick MD, Strieter RM. Cisplatin inhibits the production of monocyte-derived interleukin-1 receptor antagonist. *Clin Res* 1992; 40:737A.
3. Arenberg DA, Kunkel SL, Standiford TJ, Burdick MD, Strieter RM. Regulation of monocyte derived interleukin-1 receptor antagonist by cisplatin. *Clin Res* 1993; 41:309A.
4. Arenberg DA, Smith DR, Kunkel SL, Standiford TJ, Rolfe MW, Lynch III JP, Burdick MD, Wilke CA, Hampton JN, Orringer MB, Whyte RI, Strieter RM. Increased interleukin-1 receptor antagonist in idiopathic pulmonary fibrosis. Presented at the University of Michigan Department of Internal Medicine Research Day, April 16, 1994.
5. Danforth JM, Strieter RM, Kunkel SL, Arenberg DA, VanOtteren GM, Standiford TJ. Lipoteichoic acid induces the gene expression of chemotactic cytokines from human blood monocytes. *Am Respir Crit Care Med* 1994; 149:A871.

6. Arenberg DA, Smith DR, Kunkel SL, Standiford TJ, Rolfe MW, Lynch III JP, Burdick MD, Wilke CA, Orringer MB, Whyte RI, Strieter RM. Interleukin-1 receptor antagonist protein is increased in idiopathic pulmonary fibrosis. *Clin Res* 1994; 42:351A.
7. Arenberg DA, Polverini P, Kunkel S, Burdick M, Strieter R. C-X-C chemokines display disparate angiogenic activity. *FASEB J* 1995; 9:A587.
8. Burdick M, Kunkel S, Standiford T, Smith D, Arenberg DA, Rolfe M, Lynch J III, Glass M, Wilke C, Orringer M, Whyte R, Strieter R. Increased interleukin-1 receptor antagonist protein in idiopathic pulmonary fibrosis: a compartmental analysis. *FASEB J* 1995; 9:A431.
9. Arenberg DA, Kunkel SL, Greenspoon SL, Burdick MD, Polverini PJ, Strieter RM. The expression of C-X-C chemokines during tumorigenesis: A possible role for regulation of angiogenesis. *Am J Respir Crit Care Med* 1995; 151:A211.
10. Arenberg DA, Kunkel SL, Burdick MD, Polverini PJ, Strieter RM. Treatment with anti-IL-8 inhibits non-small cell lung cancer tumor growth. Presented at the Fourth International Chemokine Symposium in Bath, UK. June 1995.
11. Strieter RM, Polverini PJ, Shanafelt AB, Arenberg DA, Burdick MD, Van Damme J, Walz A, Kunkel SL. The CXC chemokine family displays disparate angiogenic activity: The role of these cytokines in human non-small cell lung cancer (NSCLC). Presented at the Fourth International Chemokine Symposium in Bath, UK. June 1995.
12. Arenberg DA, Kunkel SL, Greenspoon SL, Burdick MD, Polverini PJ, Strieter RM. The expression of CXC chemokines during tumorigenesis: A possible role for regulation of angiogenesis. Fourth International Chemokine Symposium. Bath, UK. June 1995.
13. Arenberg DA, Kunkel SL, Burdick MD, Polverini PJ, Strieter RM. Treatment with anti-IL-8 inhibits non-small cell lung cancer tumor growth. *J Invest Med* 1995; 43:479A.
14. Arenberg DA, Kunkel SL, Polverini PJ, Whyte RI, Iannettoni M, Burdick MD, Glass M, Morris S, DiGiovine B, Strieter RM. IP-10 is a potent angiostatic CXC chemokine in non-small cell lung cancer (NSCLC). *Am J Respir Crit Care Med* 1996; 153:A672.
15. DiGiovine B, Lynch JP, Martinez FJ, Flint A, Whyte RI, Iannettoni MD, Arenberg DA, Burdick MD, Glass MC, Morris SB, Kunkel SL, Strieter RM. IL-8 is elevated in lung transplant recipients with obliterative bronchiolitis. *Am J Respir Crit Care Med* 1996; 153:A152.
16. DiGiovine B, Lynch JP, III, Martinez FJ, Flint A, Whyte RI, Iannettoni M, Arenberg DA, Burdick MD, Glass MC, Morris SB, Kunkel SL, Strieter RM. Neutrophilic alveolitis in obliterative bronchiolitis after lung transplantation: Role of interleukin-8. *FASEB J* 1996; 10:A1194.
17. Arenberg DA, Kunkel S, Polverini P, Whyte R, Iannettoni M, Burdick M, Glass M, Morris S, DiGiovine B, Strieter R. Interferon-gamma inducible protein 10 (IP-10) inhibits tumor growth of non-small cell lung cancer (NSCLC). *FASEB J* 1996; 10:A1472.
18. Sullivan TD, Kunkel SL, Burdick MD, Glass MC, Arenberg DA, DiGiovine B, Morris SB, Strieter RM. Prostaglandin E2 augments the production of two pro-inflammatory chemokines (ENA-78 and GRO-a). *FASEB J* 1996; 10:A1485.
19. Arenberg DA, Kunkel S, DiGiovine B, Whyte R, Iannettoni M, Smith D, Glass M, Burdick M, Strieter R. C-C chemokine levels are elevated in human lung cancer. *J Invest Med* 1996; 44:276A.
20. Arenberg DA, Kunkel S, Polverini P, Whyte R, Iannettoni M, Burdick M, Glass M, Morris S, DiGiovine B, Strieter R. Interferon-gamma inducible protein 10 (IP-10) regulates tumor growth, angiogenesis, and metastasis in non-small cell lung cancer (NSCLC). AFCR-Midwest-Chicago, IL, September 19-21, 1996.
21. DiGiovine B, Whyte RI, Iannettoni MD, Arenberg DA, Burdick MD, Glass MC, Morris SB, Kunkel SL, Strieter RM. CXC chemokine composition of stage 1 and stage 2 adenocarcinomas of the lung correlates with clinical outcome. AFCR-Midwest-Chicago, IL, September 19-21, 1996.
22. DiGiovine B, Lynch JP, Martinez FJ, Flint A, Whyte RI, Iannettoni MD, Florn R, Arenberg DA, Burdick MD, Glass MC, Morris SB, Kunkel SL, Strieter RM. Interleukin-1 receptor antagonist is elevated in lung transplant recipients with obliterative bronchiolitis. *CHEST* 1996, San Francisco, CA, October 27-31, 1996.
23. DiGiovine B, Lynch JP, Martinez FJ, Whyte RI, Iannettoni MD, Hariharan K, Arenberg DA, Burdick MD, Glass MC, Morris SB, Kunkel SL, Strieter RM. The presence of pro-fibrotic cytokines correlates with outcome in patients with idiopathic pulmonary fibrosis. *CHEST* 1996, San Francisco, CA, October 27-31, 1996.

24. Arenberg DA, Kunkel SL, Polverini PJ, Burdick MD, Glass M, Morris S, Strieter RM. Interferon-inducible protein 10 (IP-10) prolongs survival in a mouse model of non-small cell lung cancer (NSCLC). *Am J Respir Crit Care Med* 1997; 155(4):A500. Presented at the American Thoracic Society, San Francisco, CA, May, 1997.
25. DiGiovine B, Lynch JP, Martinez FJ, Flint A, Whyte RI, Iannettoni MD, Florn R, Arenberg DA, Burdick MD, Glass MC, Morris SB, Kunkel SL, Strieter RM. CXC chemokine composition of stage I adenocarcinoma of the lung correlates with clinical outcome. *Am J Respir Crit Care Med* 1997; 155(4):A37. Presented at the American Thoracic Society, San Francisco, CA, May, 1997.
26. Keane M, Arenberg DA, Burdick M, Wilke C, Morris S, Glass M, Kunkel S, Strieter R. CXC chemokines are important regulators of angiogenic activity in IPF. *Am J Respir Crit Care Med* 1997; 155(4):A315. Presented at the American Thoracic Society, San Francisco, CA. May 1997.
27. Arenberg DA, DiGiovine B, Morris S, Burdick M, Kunkel S, Polverini P, Strieter R. Angiogenesis mediated by ENA-78 promotes growth of human non-small cell lung cancer (NSCLC). *FASEB J* 1997; 11(3) A544, New Orleans, LA.
28. Keane M, Arenberg D, Burdick M, Wilke C, Morris S, Glass M, Kunkel S, Strieter R. The angiostatic CXC chemokines IP-10 and MIG are reduced during the pathogenesis of bleomycin-induced pulmonary fibrosis. *FASEB J* 1997; 11(3) A228. New Orleans, LA.
29. Arenberg DA, Kunkel S, Keane M, Glass M, Morris S, Burdick M, Strieter R. Human lung cancers recruit macrophages via expression of CC chemokines. Midwest AFMR, Chicago, IL, September 25-27, 1997.
30. Arenberg DA, Kunkel SL, Polverini PJ, Burdick MD, Glass M, Morris S, Strieter RM. Interferon- $\gamma$  inducible protein 10 (IP-10) dependent angiostatic activity prolongs survival in a model of non-small cell lung cancer (NSCLC). Submitted to Gordon Research Conference, Angiogenesis and Microcirculation, Newport, RI. August 17-22, 1997.
31. Arenberg DA, DiGiovine B, Keane M, Morris S, Burdick M, Kunkel S, Strieter R. Inhibition of epithelial neutrophil activating peptide (ENA-78) reduces growth and angiogenesis of human non-small cell lung cancer. *Am J Respir Crit Care Med* 1998; 157(3):A756.
32. Arenberg DA, Keane M, Kunkel S, Glass M, Morris S, Burdick M, Strieter R. Tumor associated macrophages and CC chemokines in human lung cancers. *FASEB J* 1998; 12(5):A890. Presented at Experimental Biology 98, San Francisco, CA.
33. Addison CL, Arenberg DA, Xue Y, Morris SB, Wilke C, Glass MC, Burdick MD, Strieter RM. Inhibition of tumor growth and neovascularization by overexpression of the non-ELR CXC chemokine MIG. *FASEB J* 1998; 12(5), A278.
34. Arenberg DA, Keane M, DiGiovine B, Kunkel S, Morris S, Xue Y, Burdick M, Glass M, Iannettoni M, and Strieter R. Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. Submitted to Gordon Research Conference on Chemotactic Cytokines, Heniker, NH. June 1998.
35. Klemptner A, Arenberg DA. Invasive mucormycosis in a patient with chronic obstructive pulmonary disease. Michigan Chapter Meeting of ACP May 1998.
36. Counsell R, Arenberg DA, Gross M, Lehr J, Longino M, Pienta K, Pinchuk A, Rampy M, Skinner R, Weichert J. Synthesis and tumor imaging properties of a homologous series of radioiodinated alkylphosphatidyl cholines. XVth International Congress on Medicinal Chemistry, September 1998.
37. Arenberg DA, Keane M, Kunkel S, Strom S, Burdick M, and Strieter R. Tumor interaction with macrophages in lung cancer. Keystone Symposium: Chemokines and chemokine receptors. Keystone, CO, January 1998.
38. Strieter RM, Keane MP, Arenberg DA. CXC chemokines in the regulation of angiogenesis. Keystone Symposium: Chemokines and chemokine receptors. Keystone, CO, January 1998.
39. Keane MP, Moore TA, Moore BB, Arenberg DA, Belperio JA, Wilke CA, Burdick MD, Taub DD, Strieter RM. Production and function of C10 during bleomycin-induced pulmonary fibrosis. Keystone Symposium: Chemokines and chemokine receptors. Keystone, CO, January 1998.
40. Arenberg DA, Zlotnick A, Strom S, Burdick M, and Strieter R. Inhibition of lung cancer growth by the novel chemokine 6Ckine. *Am J Respir Crit Care Med* 1999; 159(3):A746.
41. Arenberg DA, Strom S, Keane M, Kunkel S, Burdick M, Strieter R. Angiostatic and anti-tumor activity of interferon- $\gamma$  (IFN $\gamma$ ) in SCID mice. *Am J Respir Crit Care Med* 2000; 161(3):A678.
42. Arenberg DA, Strom S, Keane M, Kunkel S, Burdick M, Strieter R. Macrophage infiltration in human



- and experimental lung cancer: The role of CC chemokines. *FASEB J* 1999; 13(4):A304.
43. Keane MP, Belperio JA, Arenberg DA, Burdick MD, Strieter RM. IL-12 attenuates bleomycin-induced pulmonary fibrosis by inducing expression of IFN- $\gamma$ . *Am J Respir Crit Care Med* 2000; 161(3):A751.
  44. White ES, Strom SR, Arenberg DA. In vitro interaction between non-small cell lung cancer cells and monocytes. *Am J Respir Crit Care Med* 2000; 161(3):A678.
  45. Arenberg DA, Strom S, Kunkel S, Burdick M, Strieter R. Monocyte angiogenic activity induced by lung cancer cell lines. *FASEB J* 2000; 14(4):A20.
  46. White ES, Strom SR, Arenberg D. Modulation of macrophage-derived angiogenic activity of extracellular matrix proteins. *FASEB J* 2000; 14(4):A20.
  47. White ES, Wys N, Strom SR, Arenberg D. Fibronectin is a Key Mediator of Macrophage-Derived Angiogenic Activity. Submitted to: Cytokines and Cancer: Regulation, Angiogenesis, and Clinical Applications. American Association for Cancer Research. September 20-24, 2000.
  48. Arenberg DA, Wys N, White ES, Migration inhibitory factor (MIF) expression in lung cancer promotes angiogenesis. *Am J Respir Crit Care Med* 2001; 161(3):A678.
  49. White ES, Wys NL, and Arenberg DA. Fibronectin binding, via  $\alpha_5\beta_1$ -integrin, increases macrophage-derived angiogenic activity. *Am J Respir Crit Care Med* 2001; 161(3):A678.
  50. Arenberg DA, Wys NL, and White E. Induction of chemokine dependent angiogenic activity by macrophage migration inhibitory factor (MIF). Keystone Symposium on Chemokines and Chemokine receptors, Taos, NM, February 2001.
  51. Arenberg DA and Wys N. Inhibition of lung cancer derived chemokine expression by atorvastatin. *FASEB J* 2001; 15(4):A.
  52. Arenberg DA, White E and Carskaddon S. Macrophage infiltration of murine lung cancer tumors: role in angiogenesis. *Am J Respir Crit Care Med* 2002; 165:A105.
  53. Lama VN, Arenberg D, Flaherty K, Moore B, Kazerooni E, Standiford T, Toews G, Martinez FJ. Macrophage migration inhibitory factor (MIF) in pulmonary fibrosis. *Am J Respir Crit Care Med* 2002; 165:A172.
  54. White ES, Carskadon SL, Livant DL, Markwart S, Toews GB, Arenberg DA. Fibrotic-lung fibroblast invasion of basement membranes is modulated by PTEN. *Am J Respir Crit Care Med* 2002; 165:A362.
  55. Arenberg DA, Carskaddon S, White ES. Expression of macrophage migration inhibitory factor (MIF) in human non-small cell lung cancer (NSCLC). Midwest Section-AFMR, Chicago, IL. September. 2002.
  56. Keshamouni V, Joel B, Reddy R, Arenberg DA, Standiford T. Evidence for Selective PPAR Modulation in Lung Cancer. Submitted to Keystone Symposia on PPAR. Feb 2003.
  57. Arenberg DA, White ES, Carskaddon S. Macrophage Migration Inhibitory Factor (MIF) Promotes Chemokine Mediated Angiogenesis In Lung Cancer. ATS, 2003, Seattle, WA.
  58. Keshamouni V, Reddy R, Joel B, Arenberg DA, Newstead M, Standiford T. Peroxisome Proliferator-Activated Receptor (PPAR) Agonists Impede Growth in Non-Small Cell Lung Cancer By Inhibiting Cell Proliferation and Angiogenesis. Submitted to ATS. 2003, Seattle WA.
  59. Keshamouni V, Arenberg DA, Joel B, Reddy R, Standiford T, Thannickal VJ. Redox regulation of apoptotic resistance in lung cancer cells. Submitted to ATS. 2003, Seattle WA.
  60. White ES, Carskadon SL, Dickey EG, Arenberg DA. Basement Membrane Invasion by Lung Fibroblasts from IPF: Role of paxillin and pp125FAK. Submitted to ATS. 2003, Seattle WA.
  61. White ES, Carskadon SL, Dickey EG, Arenberg DA. Invasive Behavior of Lung Fibroblasts from Fibrotic Diseases: Role of the  $\alpha_4\beta_1$  and  $\alpha_5\beta_1$  Integrins. Submitted to ATS. 2003, Seattle WA.
  62. Arenberg DA, Carskadon SL, Thannickal VJ. H<sub>2</sub>O<sub>2</sub>-dependent Expression of Angiogenic CXC Chemokines by Human Non-Small Cell Lung Cancer Cells. Submitted to AACR, Toronto, Ontario CA. April 2003.
  63. Arenberg DA, Carskadon SL, Thannickal VJ. GP91phox-dependent Expression of Angiogenic CXC Chemokines in Human Non-Small Cell Lung Cancer. Submitted to The Thomas Petty Aspen Lung Conference, June 2003.
  64. Arenberg DA, Gray A, Carskadon SL, White ES. Tumor Derived Fibroblasts in Lung Cancer; A Distinct Sub-population of Lung Fibroblasts. AACR, Orlando, FL. March 2004.
  65. Arenberg DA, Carskadon SL, Thannickal VJ and Keshamouni, V. Oxidase-Dependent Expression of Angiogenic Activity by Non-small Cell Lung Cancer Cells, American Thoracic Society. Orlando, FL. May 2004.

66. McClelland M, Gray A, Carskadon S, Zhao L, and Arenberg D. Macrophage migration inhibitory factor (MIF)-dependent induction of angiogenic CXC chemokines in an animal model of NSCLC. AACR Conference: Molecular Pathogenesis of Lung Cancer, San Diego, CA.
67. McClelland M, Gray A, Carskadon S, Zhao L, and Arenberg DA. Angiogenic Strategies in Non-Small Cell Lung Cancer. AACR Conference: Molecular Pathogenesis of Lung Cancer, San Diego, CA.
68. McClelland M, Gray A, Carskadon S, Zhao L, and Arenberg DA. Tumor derived fibroblasts are pro-angiogenic. American Thoracic Society, San Diego, CA. May 2005.
69. McClelland MR, Carskadon SL, Zhao L, White ES, Arenberg DA. Diversity and plasticity of the angiogenic switch in lung cancer. American Thoracic Society, San Diego, CA. May 2006.
70. Arenberg DA, Carskadon SL, Zhao L, White ES, McClelland MR. The tumor microenvironment modulates the angiogenic phenotype in lung cancer. Diversity and plasticity of the angiogenic switch in lung cancer. American Thoracic Society, San Francisco, CA. May 2007.
71. Arenberg DA, Carskadon SL, Zhao L. Lung injury accelerates growth of lung cancer cells in an orthotopic model of lung cancer Submitted to American Thoracic Society, Toronto, ON, CA. May 2008.
72. Arenberg DA, Carskadon SL, Zhao L, McMillan T, McClelland MR. Macrophage Migration Inhibitory Factor (MIF) Is Both Necessary and Sufficient To Accelerate the Growth of Lung Cancer Tumors in the Context of Injured Lung. [Publication Page: A5130]. ATS International Conference, San Diego, CA.
73. Quintana R, Arenberg DA, Montgrain PR, Carskadon SL, Deftos LJ, Hastings RH. Parathyroid Hormone-Related Protein Expression in NSCLC Predicts Improved Survival, [Publication Page: A2678] ATS International Conference, San Diego, CA.
74. Freeman CM, Martinez FJ, Polak T, Han MK, Chensue SW, Murphy HS, Arenberg DA, Meldrum CA, Getty C, Curtis JL. Engagement of TLR3 on CD8+ T Cells from COPD Patients Increases In Vitro Production of IFN, TNF, and Perforin, [Publication Page: A3950] ATS International Conference, San Diego, CA.